Skip to main content

Table 3 Univariate and multivariate analysis of covariables associated with overall survival from the start of second-line chemotherapy

From: Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study

Variables Univariate p-value Multivariate p-value
HR HR
(95% CI) (95% CI)
Second-line chemotherapy
 Platinum-doublet vs Single agent 0.54  < 0.01 0.53  < 0.01
(0.40 to 0.73)   (0.39 to 0.73)  
Age
  ≥ 75 years vs < 75 years 0.79 0.41 0.82 0.51
(0.45 to 1.34)   (0.45 to 1.49)  
Sex
 Female vs Male 0.57 0.02 0.55 0.01
(0.36 to 0.91)   (0.34 to 0.88)  
ECOG PS
 0/1 vs 2 2.15 0.28 2.59 0.19
(0.53 to 8.65)   (0.63 to 10.6)  
Smoking status
 Never or former smoker vs Current smoker 0.84 0.23 0.94 0.70
(0.63 to 1.12)   (0.70 to 1.27)  
Histology
 Adenocarcinoma vs Non-adenocarcinoma 0.98 0.87 1.14 0.38
(0.73 to 1.30)   (0.85 to 1.54)  
Clinical stage
 IIIA vs IIIB 0.62  < 0.01 0.67  < 0.01
(0.47 to 0.82)   (0.50 to 0.90)  
Respiratory comorbidity
 No vs Yes 0.95 0.95 0.95 0.75
(0.71 to 1.27)   (0.70 to 1.29)  
Response to first-line chemoradiotherapy
 CR or PR vs not CR nor PR 0.94 0.71 0.94 0.72
(0.70 to 1.28)   (0.68 to 1.30)  
Duration from the start of first-line therapy to second-line therapy
  ≥ 8.6 months vs < 8.6 months 0.82 0.16 0.74 0.048
(0.62 to 1.08)   (0.55 to 0.997)  
  1. CI confidence interval, CR complete response, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, PR partial response